Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Miller, David S., Filiaci, Virginia L., Mannel, Robert S., Cohn, David E., Matsumoto, Takashi, Tewari, Krishnansu S., DiSilvestro, Paul, Pearl, Michael L., Argenta, Peter A., Powell, Matthew A., Zweizig, Susan L., Warshal, David P., Hanjani, Parviz, Carney, Michael E., Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
RAPID COMMUNICATIONS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676887/
https://ncbi.nlm.nih.gov/pubmed/33078978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01076
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller